MedTrace Logo

Acute Effects of Cinacalcet on Arterial Stiffness and Ventricular Function in Hemodialysis Patients

NCT01250405 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2014-04-07

No results posted yet for this study

Summary

The primary objective is to determine whether reduction of serum calcium concentration by cinacalcet leads to reduction of mean blood pressure adjusted c-fPWV. The secondary objectives are to study the effects of calcium reduction on 1) carotid-radial PWV (c-rPWV), 2) common carotid artery (CCA) biomechanics, 3) pulse wave profile and cardiac function.

Conditions

Interventions

DRUG

Cinacalcet

One sequence receives Cinacalcet 30mg /d for 7 days followed by placebo for 7 days

DRUG

Placebo

One sequence receives placebo for 7 days followed by Cinacalcet 30mg/d for 7 days

Sponsors & Collaborators

  • Amgen

    collaborator INDUSTRY

  • Laval University

    lead OTHER

Principal Investigators

  • Mohsen Agharazii, MD · Laval University

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2014-04-30
Completion
2014-04-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01250405 on ClinicalTrials.gov